Press Releases

Cardinal Health Awarded FDA Funding to Assess Real World Evidence Results Against Clinical Trials

Cardinal Health will explore how to better standardize real world evidence for use in regulatory decisions

Rho’s Chief Medical Officer Jack Modell Presenting During 12th Annual CNS Summit

Rho, a full-service contract research organization (CRO), is showcasing its clinical development expertise during the 12th Annual CNS Summit, taking place at the Encore Boston Harbor Hotel from November 7-10, 2021. Rho’s Chief Medical Officer, Dr. Jack Modell, along with Dr. John Greist and Dr. Thomas Laughren, will present during a Spotlight Session at the Summit. The 50-minute breakout session, titled, “The Seven Essentials of Clinical Development: How to Avoid Shooting Yourself in the Foot” will showcase the speakers’ combined experience in clinical medicine, academic research, regulatory affairs, and development of drugs and medical applications of information technology.

Two Top 5 Global Pharmaceutical Companies Affirm Their Trust in Calyx RIM, Execute Long-Term Contract Extensions

Ability to meet evolving requirements, including IDMP, ensures regulatory compliance for leading companies

Rho to Coordinate NIAID COVID‐19 Vaccine Study in Autoimmune Disease Non‐Responders

Rho , a full-service contract research organization (CRO) with a proven track record of drug development success, today announced that it will be the Statistical and Clinical Coordinating Center for the COVID-19 Vaccine in Autoimmune Disease Non-Responders study. This clinical trial will assess the antibody response to an extra dose of an authorized or approved COVID-19 vaccine in people with autoimmune diseases who did not respond to an original COVID-19 vaccine regimen. The trial also will investigate whether pausing immunosuppressive therapy for autoimmune diseases improves the antibody response to an extra dose of a COVID-19 vaccine in this population. The Phase 2 trial is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and is being conducted by the NIAID-funded Autoimmunity Centers of Excellence.

Panthera@theRutherford clinical trial partnership has commenced the first UK multicentre oncology trial in prostate cancer with ten more oncology trials in the pipeline

The first multisite oncology trial undertaken by the independent sector in the UK has started treating its first patient at the Rutherford Cancer Centre North East.

Emmes launches Orphan Reach™: Emmes’ Rare Disease Center

The new global Rare Disease center of Emmes expects accelerating growth from US and European biotechs

TARA Biosystems Partners with Scipher Medicine®

TARA Biosystems, a biotechnology company harnessing human biology and data to transform cardiac drug discovery, today announced a collaboration with Scipher Medicine, a precision medicine company matching patients with the most effective therapy. The collaboration will address a critical unmet need for effective therapeutics in cardiac laminopathies.

Curebase, LEVEL Announce Clinical Trial to Determine Whether Cannabinoids Can Help Veterans Sleep Better

Curebase, LEVEL Announce Clinical Trial to Determine Whether Cannabinoids Can Help Veterans Sleep Better

eClinical Solutions Enhances elluminate Clinical Data Cloud with RBQM

eClinical Solutions LLC, a global provider of cloud-based enterprise software and software-driven clinical data services that accelerate digital clinical initiatives, announced the inclusion of its Risk-Based Quality Management (RBQM) offering within the elluminate Clinical Data Cloud. With this offering, clinical teams can transform numerous data streams into actionable analytics and statistically significant insights for a holistic, risk-based monitoring approach.

Vanessa Biotech receives approval from Ghana FDA to proceed with Cholera Phase II Clinical Trial

Vanessa Biotech (VB) is a biomedical company founded on the desire to “give hope where none existed” by making an impact on healthcare markets often overlooked. Its continually expanding pipeline of innovative pharmaceuticals, medical devices and consumer and public health products reflects the company’s inventive nature and commitment to delivering solutions that increase access to quality care. The company’s flagship product, Shylicine™, is the first-ever drug developed to treat the rare and lethal microvillus inclusion disease. Vanessa Biotech, a University of Connecticut Technology Incubation Program participant, has global offices in Hungary, Spain, and Germany in addition to its Hamden, Conn. corporate campus.

CPhI Worldwide Report: CMOs will account for four of the five top bio manufacturing capacities in 2025

230 Covid-19 supply agreements known, with demand for larger biocapacity remaining constrained as a consequence of the circa 1000 vaccines in development

Aragen expects to ride wave of US biotech growth in 2022 – influx of discovery capital is surging demand for CDMO services

Company plans wide ranging investments and expansions to keep pace with demand driven by macro-changes and diversifying client base

Clinical Ink Acquires Digital Artefacts

Clinical Ink — a global clinical trial data and technology company and leader in eSource and decentralized clinical trial conduct — today announced its acquisition of Digital Artefacts, a digital endpoint-based technology company with an unrivaled modular platform for complex cognitive, behavioral, and physiological data capture.

BROOKS AUTOMATION ANNOUNCES NEW AGREEMENT WITH QTC MANAGEMENT, INC. TO SUPPORT THE MILITARY RESERVE HEALTH READINESS PROGRAM

Brooks Automation has announced that its newly branded Azenta Life Sciences business has been contracted by QTC Management, Inc. to provide the storage and distribution of vaccines to the U.S. Department of Defense.

Noxopharm Announces DARRT-2 Clinical Trial in U.S.

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced its DARRT-2 Phase 2 clinical trial has commenced with patient enrollment in the U.S.

Crucial Data Solutions Announces New Public Patient Registry Feature for Mobile App

CDS’ eClinical platform, TrialKit, now offers sponsors and CROs the ability to create global registries in which the public can self-enroll and participate in studies from their mobile device

BioIVT to Showcase Use of a Sandwich-cultured Human Hepatocyte Model to Study Drug-Drug Interactions

Researchers will describe how they used a transporter-competent SCHH model to investigate the DDI potential of bempedoic acid, a drug indicated for hypercholesterolemia.

MedExecWomen Empowers Women in Leadership Roles in the Medical Device Diagnostics and Digital Health Industries

MedExecWomen, an organization dedicated to empowering women in leadership roles in the medical device, diagnostics, drug delivery, and digital healthcare industries, hosted the second annual MedExecWomen conference on October 26, 2021, in Boston, MA.

Samsung Biologics Reports Strong Second Quarter 2021 Financial Results

Mateo Iglesias Vice President Marketing & Sales Sakura Finetek Europe

Sakura Finetek Europe has announced the appointment of Mr. Mateo Iglesias as Vice President of Marketing & Sales EMEAI.